The Pathology and Tissue Resources Core will provide routine and innovative tissue resources and materials essential for achieving the aims of the SPORE projects. Routine materials include tumors and non-malignant lung specimens and tumor cell lines. Over 3,000 tumors and 300 lung cancer cell lines have been banked, and over 50,000 aliqouts of tumor or cell line pellets, RNA or DNA or paraffin sections have been distributed to investigators.
Our Aim 1 is to collect, process, store, catalog and distribute tissues, cell lines and blood specimens, both malignant and nonmalignant, and relevant clinico-pathologic and molecular data, as requested by the various component projects of the SPORE program.
Aim 2 is to develop and utilize innovative and routine tissue and cell line resources that will aid in the successful completion of the SPORE program aims. These include development of new tumor cell line resources to complement recent genome wide mutation data on lung cancer oncogenotypes.
Aim 3 is to perform and interpret tissue-based molecular methodologies in close collaboration with the component projects of the SPORE program to satisfy their approved aims. This will involve developing molecular assays that eventually can be deployed as CLIA certified lab tests to facilitate the planned translational science clinical trials in most of the SPORE projects. This Core will play a crucial role on promoting collaboration among our own SPORE investigators, investigators at other Lung Cancer SPORE sites, and investigators at our own and other institutions including other peer-reviewed projects funded by NCI/NIH and other agencies. All of our SPORE projects will utilize Core B materials and services. Heavy utilization of our routine and innovative materials, and close interactions with the SPORE investigators will greatly aid the successful completion of the aims of our SPORE proposal.
All of the proposed lung cancer translational research is critically dependent on tumor and cell line resources provided by this Core. These include both the detailed clinical, and genome wide molecular annotation of many of the tumor and cell line specimens. These resources will also greatly facilitate inter-SPORE and inter-institutional collaborations.
|Akbay, Esra A; Kim, James (2018) Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. Transl Lung Cancer Res 7:464-486|
|Zhang, Wei; Girard, Luc; Zhang, Yu-An et al. (2018) Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. Transl Lung Cancer Res 7:32-49|
|Tan, Xiaochao; Banerjee, Priyam; Liu, Xin et al. (2018) The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest 128:1267-1282|
|McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29|
|Walser, Tonya C; Jing, Zhe; Tran, Linh M et al. (2018) Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells. Cancer Res 78:1986-1999|
|Skoulidis, Ferdinandos; Goldberg, Michael E; Greenawalt, Danielle M et al. (2018) STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov 8:822-835|
|Zhou, Xiaorong; Padanad, Mahesh S; Evers, Bret M et al. (2018) Modulation of Mutant KrasG12D -Driven Lung Tumorigenesis In Vivo by Gain or Loss of PCDH7 Function. Mol Cancer Res :|
|Ferdosi, Shadi; Rehder, Douglas S; Maranian, Paul et al. (2018) Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, ?1-4 Branching, ?1-6 Branching, and ?2-6 Sialylation in Cancer. J Proteome Res 17:543-558|
|Pietanza, M Catherine; Waqar, Saiama N; Krug, Lee M et al. (2018) Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin Oncol 36:2386-2394|
|Abrams, Zachary B; Zucker, Mark; Wang, Min et al. (2018) Thirty biologically interpretable clusters of transcription factors distinguish cancer type. BMC Genomics 19:738|
Showing the most recent 10 out of 1059 publications